Megan Hollasch is a journalist who specializes in covering oncology and cancer research. She has written for various publications including OncLive, Cancer Network, and Oncology Nursing News. Megan's articles focus on the latest advancements in cancer treatment, research, and emerging therapies.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Megan Hollasch's coverage predominantly focuses on healthcare and pharmaceuticals, with an emphasis on cancer research and targeted therapies. Her articles often cite data to support the presented findings. When reaching out to her, consider providing access to credible sources of recent data or studies related to the topics she covers.
Given Megan’s focus on citing data in her articles, she would likely be receptive to pitches that include access to new clinical trial results, statistical analyses, or other relevant quantitative information from reputable sources within the healthcare and pharmaceutical fields.
Since there is no specific geographic focus mentioned for Megan's coverage attributes, it is advisable to tailor outreach efforts towards globally relevant healthcare and pharmaceutical developments in cancer research and targeted therapies.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ryan Scott, Megan Hollasch
Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.
By: Megan Hollasch, Ryan Scott
John H. Strickler, MD, discusses treatment with telisotuzumab adizutecan for CRC as well as this ADC’s potential to broaden the CRC treatment paradigm.
By: Ashling Wahner, Megan Hollasch
Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.
By: Ryan Scott, Megan Hollasch
Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.
By: Courtney Flaherty, Megan Hollasch
Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.
By: Ryan Scott, Megan Hollasch, Chris Ryan
Nataliya Uboha, MD, PhD, discusses the evolving treatment landscape for patients with gastric, gastroesophageal junction, and esophageal cancers.
By: Ryan Scott, Megan Hollasch
An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.
By: Megan Hollasch, Caroline Seymour
ctDNA shows promise in predicting recurrence risk and guiding adjuvant chemotherapy decisions in colon cancer.
By: Courtney Flaherty, Megan Hollasch
Nataliya Uboha, MD, PhD, discusses the FDA’s ODAC’s recommendation to restrict anti–PD-1 agents to patients with PD-L1–positive ESCC.
By: Megan Hollasch, Caroline Seymour
Anita Scheuber, MD, PhD, details the mechanism of action of NDI-101150, early data seen with the agent, and next steps in the HPK1 inhibitor’s investigation.
(833) 317-6278 